Kathryn T Hall

Title: Kathryn T Hall: Innovator in Nucleic Acid Research

Introduction

Kathryn T Hall is a prominent inventor based in Boston, MA (US). She has made significant contributions to the field of nucleic acid research, holding 2 patents that focus on novel CD100 molecules. Her work has implications for understanding and manipulating immune responses.

Latest Patents

Hall's latest patents include innovations related to nucleic acids encoding CD100 molecules. These isolated nucleic acid molecules stimulate leukocyte responses, such as B cell aggregation, differentiation, survival, and T cell proliferation. The novel CD100 molecules exhibit homology to semaphorins, which are critical for guiding the growth of axons in neurons. In addition to isolated nucleic acids, her patents describe antisense nucleic acid molecules, recombinant expression vectors, and host cells that incorporate these vectors. Furthermore, her inventions provide isolated CD100 proteins, fusion proteins, and active fragments, along with diagnostic and therapeutic methods utilizing these compositions.

Career Highlights

Throughout her career, Kathryn T Hall has worked with esteemed organizations, including the Dana-Farber Cancer Institute and the Institut National De La Santé Et De La Recherche Médicale. Her research has significantly advanced the understanding of immune responses and potential therapeutic applications.

Collaborations

Hall has collaborated with notable colleagues, including Gordon James Freeman and Joachim L Schultze. These partnerships have contributed to her innovative research and the development of her patents.

Conclusion

Kathryn T Hall's work in nucleic acid research exemplifies her commitment to advancing medical science. Her patents on CD100 molecules highlight her innovative contributions to immunology and therapeutic development.